EUCTR2021-004131-84-NL进行中（未招募）1 期
Chronotherapy in Inflammatory Arthritis (ChronIA trial): a crossover randomized controlled trial comparing the effectiveness of morning and evening dosing of tofacitinib extended-release - ChronIA trial
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- •- RA or PsA, , according to respectively the ACR/EULAR 2010 criteria for RA and CASPAR criteria
- •- Active disease, respectively defined as a DAS>2.4 or DAPSA>14
- •- <3 bDMARDs used
- •- Age =18 years
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 64
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •- Current or previous treatment of arthritis with tsDMARD(s)
- •- Prednisone (or equivalent) usage at a dose of >7.5mg
- •- Work in shifts
- •- (Relative) contraindications for study medication:
- •a. Evidence of ongoing infectious or malignant process obtained within 3 months prior to screening and evaluated by a qualified health care professional.
- •b. Pregnant or nursing (lactating) women.
- •c. Female participants of child bearing potential and male participants whose partner is of child bearing potential who are not willing to ensure that they or their partner use effective contraception during the trial and for 3 months thereafter as in standard practice.
- •d. History of clinically significant liver disease or liver injury as indicated by abnormal liver function tests (LFT) such as aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT), alanine aminotransferase/ serum glutamic pyruvic transaminase (ALT/SGPT), alkaline phosphatase, or serum bilirubin. The Investigator should be guided by the following criteria: Any single parameter may not exceed 2 x upper limit of normal (ULN). A single parameter elevated up to and including 2 x ULN should be re-checked once more as soon as possible, and in all cases, at least prior to enrolment/randomization, to rule out laboratory error.
- •e. History of renal trauma, glomerulonephritis, or subjects with one kidney only, or a glomerular filtration rate (GFR) < 30 ml/min.
- •f. Other underlying metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal conditions which in the opinion of the Investigator immunocompromises the patient and/or places the patient at unacceptable risk for participation in an immunomodulatory therapy.
- •- Unable to understand, speak and write in Dutch.
研究者
相似试验
招募中
4 期
Chronotherapy in Inflammatory Arthritis (ChronIA trial): a randomized controlled trial comparing the effectiveness of morning and evening dosing of tofacitinib extended-releaseInflammatory ArthirtisJoint inflammatoin10013361NL-OMON52175Erasmus MC, Universitair Medisch Centrum Rotterdam84
进行中（未招募）
4 期
Comparing the effectiveness of morning and evening dosing of tofacitinib in inflammatory arthritisInflammatory arthritis (rheumatoid arthritis and psoriatic arthritis)Musculoskeletal DiseasesRheumatoid arthritis, unspecified, Other psoriatic arthropathiesISRCTN68663074Erasmus MC84
已完成
不适用
Development of chronotherapeutics in rheumatoid arthritisrheumatoid arthritisJPRN-UMIN000040094Department of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University120
尚未招募
4 期
Innovative Approaches to Inflammatory Arthritis: Efficacy and Safety of non-invasive transcutaneous auricular vagus nerve stimulation (IA-taVNS)Rheumatoid arthritis, SpondyloarthritisJPRN-UMIN000053649Hokkaido University20
已完成
1 期
RA morning stiffness studyRheumatoid arthritis, morning stiffnessD001172Rheumatoid ArthritisJPRN-jRCTs052210155Shima Yoshihito20